Effects of the A2A adenosine receptor antagonist KW6002 in the nucleus accumbens in vitro and in vivo

Pharmacology Biochemistry and Behavior

Volumn 83, Issue 1, 2006, Pages 114-121

  Harper, L K ^a,c   Beckett, S R ^a   Marsden, C A ^a   McCreary, A C ^b   Alexander, S P H ^a  

^a UNIVERSITY OF NOTTINGHAM   (United Kingdom)

^b Solvay Pharmaceuticals Inc   (Netherlands)

^c LOYOLA UNIVERSITY CHICAGO   (United States)

Author keywords

A2A adenosine receptors; Conditioned place preference; Dopamine release; Nucleus accumbens; Reward

Indexed keywords

4 AMINOBUTYRIC ACID; ADENOSINE A1 RECEPTOR; ADENOSINE RECEPTOR BLOCKING AGENT; DOPAMINE; ISTRADEFYLLINE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BEHAVIOR; BRAIN SLICE; CONTROLLED STUDY; DRUG EFFECT; DRUG SELECTIVITY; IN VITRO STUDY; IN VIVO STUDY; LOCOMOTION; MALE; MICRODIALYSIS; NEUROTRANSMITTER RELEASE; NONHUMAN; NUCLEUS ACCUMBENS; PRIORITY JOURNAL; RADIOASSAY; RAT;

ANIMALS; BINDING, COMPETITIVE; CONDITIONING, OPERANT; DOPAMINE; DOSE-RESPONSE RELATIONSHIP, DRUG; EXTRACELLULAR SPACE; GAMMA-AMINOBUTYRIC ACID; MALE; MICRODIALYSIS; MOTOR ACTIVITY; NUCLEUS ACCUMBENS; PURINES; RATS; RECEPTOR, ADENOSINE A2A; TRIAZINES; TRIAZOLES; XANTHINES;

ANIMALIA;

EID: 33644919650     PISSN: 00913057     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.pbb.2005.12.014     Document Type: Article

References (46)

1. E. Acquas, G. Tanda, and G. Di Chiara Differential effects of caffeine on dopamine and acetylcholine transmission in brain areas of drug-naive and caffeine-pretreated rats Neuropsychopharmacology 27 2002 182 193
2. 2A receptors in rat brain Eur J Pharmacol 411 2001 205 210
3. 2A receptor antagonist J Neurosci 20 2000 5848 5852
4. 2A receptor antagonist KW-6002 and its effect on gene expression in the rat brain Brain Res 953 2002 119
5. 2A receptor antagonist treatment of Parkinson's disease Neurology 61 2003 293 296
6. J.B. Bedingfield, D.A. King, and F.A. Holloway Cocaine and caffeine: conditioned place preference, locomotor activity, and additivity Pharmacol Biochem Behav 61 1998 291 296
7. A.-K. Cadogan, S.P.H. Alexander, E.A. Boyd, and D.A. Kendall Influence of cannabinoids on electrically-evoked dopamine release and cyclic AMP generation in the rat striatum J Neurochem 69 1997 1131 1137
8. J.F. Cheer, D.A. Kendall, and C.A. Marsden Cannabinoid receptors and reward in the rat: a conditioned place preference study Psychopharmacol 151 2000 25 30
9. 2 receptor knockout mice Proc Natl Acad Sci U S A 98 2001 1970 1975
10. 2A receptors in neuroadaptation to repeated dopaminergic stimulation: implications for the treatment of dyskinesias in Parkinson's disease Neurology 61 2003 S74 S81
11. 2A antagonist KF17837 reverses the locomotor suppression and tremulous jaw movements induced by haloperidol in rats: possible relevance to parkinsonism Behav Brain Res 148 2004 47 54
12. 2A receptor antagonism increases striatal glutamate outflow in dopamine-denervated rats Eur J Pharmacol 464 2003 33 38
13. 2A receptor antagonism potentiates l-DOPA-induced turning behaviour and c-fos expression in 6-hydroxydopamine-lesioned rats Eur J Pharmacol 321 1997 143 147
14. S. Ferre, M. Herrera-Marschitz, M. Grabowska-Anden, M. Casas, U. Ungerstedt, and N.E. Anden Postsynaptic dopamine/adenosine interaction. II. Postsynaptic dopamine agonism and adenosine antagonism of methylxanthines in short-term reserpinized mice Eur J Pharmacol 192 1991 31 37
15. A.J. Fulford, and C.A. Marsden Effect of isolation rearing on conditioned dopamine release in vivo in the nucleus accumbens of the rat J Neurochem 70 1998 384 390
16. B.E. Garrett, and S.G. Holtzman D1 and D2 dopamine receptor antagonists block caffeine-induced stimulation of locomotor activity in rats Pharmacol Biochem Behav 47 1994 89 94
17. 2A receptor antagonist Eur J Pharmacol 406 2000 345 354
18. 2A adenosine receptor inhibition of dopamine release in the rat nucleus accumbens in vitro Br J Pharmacol 137 SS 2002 [131 pp.]
19. 2A adenosine receptor antagonist KW-6002 on rat dopaminergic systems J Psychopharmacol 17 3 2003 A40
20. 2A receptors Eur J Pharmacol 431 2001 171 177
21. 2A receptor antagonist istradefylline in advanced PD Neurology 61 2003 297 303
22. 2A receptor antagonist with anticataleptic activity Eur J Pharmacol 256 1994 263 268
23. 2A receptors modify motor function in MPTP-treated common marmosets Neuroreport 9 1998 2857 2860
24. 2A antagonist KW-6002 with l-DOPA or with selective D1 or D2 dopamine agonists increases antiparkinsonian activity but not dyskinesia in MPTP-treated monkeys Exp Neurol 162 2000 321 327
25. 2A receptor-mediated striatal expression of c-fos Eur J Neurosci 18 2003 296 302
26. 2A receptor selective antagonist KW6002: research and development toward a novel nondopaminergic therapy for Parkinson's disease Neurology 61 2003 S97 S100
27. 3H]acetylcholine release J Neurochem 62 1994 960 966
28. 2A receptor is not mediated by increases in cyclic AMP J Neurochem 64 1995 2801 2809
29. 2A receptor antagonists KF17837 and KW-6002 potentiate rotation induced by dopaminergic drugs in hemi-Parkinsonian rats Eur J Pharmacol 408 2000 249 255
30. 2A receptor-mediated modulation of striatal GABA and ACh release Br J Pharmacol 113 1994 43 48
31. 2A antagonists in experimental models Adv Neurol 80 1999 121 123
32. 2A receptors in the limbic cortex, but not striatum, of aged rats J Neurochem 73 1999 1733 1738
33. 2A receptor antagonist KW-6002 in a rat model of l-DOPA-induced dyskinesia J Neurochem 84 2003 1398 1410
34. 2a receptor modulation of electrically evoked endogenous GABA release from slices of rat globus pallidus J Neurochem 60 1993 2334 2337
35. 2 receptor interaction in globus pallidus Synapse 22 1996 132 138
36. M. Morelli, S. Fenu, A. Pinna, and G. Di Chiara Adenosine A2 receptors interact negatively with dopamine D1 and D2 receptors in unilaterally 6-hydroxydopamine-lesioned rats Eur J Pharmacol 251 1994 21 25
37. 2A receptor antagonist reverses increased GABA release in the globus pallidus of unilateral 6-hydroxydopamine-lesioned rats: a microdialysis study Neuroscience 100 2000 53 62
38. G. Paxinos, and C. Watson The rat brain in stereotaxic coordinates 1997 Academic Press San Diego, CA
39. M. Pierri, E. Vaudan, T. Sager, and U. Englund KW-6002 protects from MPTP induced dopaminergic toxicity in the mouse Neuropharmacol 48 2005 517 524
40. A.E. Pollack, and J.S. Fink Synergistic interaction between an adenosine antagonist and a D1 dopamine agonist on rotational behavior and striatal c-fos induction in 6-hydroxydopamine-lesioned rats Brain Res 743 1996 124 130
41. 2A receptor stimulation enhances striatal extracellular glutamate levels in rats Eur J Pharmacol 287 1995 215 217
42. 2A receptor antagonists as new agents for the treatment of Parkinson's disease Trends Pharmacol Sci 18 1997 338 344
43. 2A antagonists with potent anti-cataleptic activity Bioorg Med Chem Lett 7 1997 2349 2352
44. 2A receptor antagonist KW-6002 on drug-induced catalepsy and hypokinesia caused by reserpine or MPTP Psychopharmacol 147 1999 90 95
45. M. Solinas, S. Ferre, Z.B. You, M. Karcz-Kubicha, P. Popoli, and S.R. Goldberg Caffeine induces dopamine and glutamate release in the shell of the nucleus accumbens J Neurosci 22 2002 6321 6324
46. 2a adenosine receptor antagonist J Pharmacol Exp Ther 276 1996 398 404